AU2020407007A1 - Biopharmaceutical compositions and related methods - Google Patents

Biopharmaceutical compositions and related methods Download PDF

Info

Publication number
AU2020407007A1
AU2020407007A1 AU2020407007A AU2020407007A AU2020407007A1 AU 2020407007 A1 AU2020407007 A1 AU 2020407007A1 AU 2020407007 A AU2020407007 A AU 2020407007A AU 2020407007 A AU2020407007 A AU 2020407007A AU 2020407007 A1 AU2020407007 A1 AU 2020407007A1
Authority
AU
Australia
Prior art keywords
seq
variant
composition
heavy chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020407007A
Other languages
English (en)
Inventor
Kelly NEELON
Mingxuan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tesaro Inc
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of AU2020407007A1 publication Critical patent/AU2020407007A1/en
Priority to AU2025203823A priority Critical patent/AU2025203823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020407007A 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods Abandoned AU2020407007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203823A AU2025203823A1 (en) 2019-12-18 2025-05-23 Biopharmaceutical compositions and related methods

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US62/949,696 2019-12-18
US201962950595P 2019-12-19 2019-12-19
US62/950,595 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203823A Division AU2025203823A1 (en) 2019-12-18 2025-05-23 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
AU2020407007A1 true AU2020407007A1 (en) 2022-06-23

Family

ID=74125707

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020407007A Abandoned AU2020407007A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods
AU2025203823A Pending AU2025203823A1 (en) 2019-12-18 2025-05-23 Biopharmaceutical compositions and related methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203823A Pending AU2025203823A1 (en) 2019-12-18 2025-05-23 Biopharmaceutical compositions and related methods

Country Status (11)

Country Link
US (1) US20230059341A1 (https=)
EP (1) EP4077388A1 (https=)
JP (2) JP2023507981A (https=)
KR (1) KR20220129548A (https=)
CN (1) CN115298218A (https=)
AU (2) AU2020407007A1 (https=)
BR (1) BR112022014694A2 (https=)
CA (1) CA3164600A1 (https=)
IL (1) IL293753A (https=)
MX (1) MX2022007464A (https=)
WO (1) WO2021126657A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
WO2024118587A1 (en) * 2022-11-30 2024-06-06 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
KR20180037275A (ko) * 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
LT3386541T (lt) * 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
AU2025203823A1 (en) 2025-06-19
JP2023507981A (ja) 2023-02-28
IL293753A (en) 2022-08-01
CN115298218A (zh) 2022-11-04
EP4077388A1 (en) 2022-10-26
CA3164600A1 (en) 2021-06-24
MX2022007464A (es) 2022-06-27
WO2021126657A1 (en) 2021-06-24
JP2026027328A (ja) 2026-02-18
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06
KR20220129548A (ko) 2022-09-23

Similar Documents

Publication Publication Date Title
AU2025201714A1 (en) Antibodies comprising modified heavy constant regions
IL293244A (en) Agonist antibodies against icos and their uses
AU2013273115B2 (en) Humanized anti-TrkA antibodies with amino acid substitutions
CN115969970A (zh) Abcg2抑制剂与sacituzumab govitecan的组合
US20150259419A1 (en) Anti-MCAM Antibodies and Associated Methods of Use
KR20180067693A (ko) 항-cd38 항체의 피하 제제 및 이의 용도
AU2020304112A1 (en) Formulations containing anti-CD47/PD-L1 bispecific antibody and preparation method therefor and use thereof
AU2025203823A1 (en) Biopharmaceutical compositions and related methods
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
BR112021006784A2 (pt) Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
TWI865617B (zh) 抗原結合蛋白
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
TW202421661A (zh) Igf1r抗體
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
BR122024025522A2 (pt) Composições biofarmacêuticas, formulação, dispositivo de injeção, meio de cultura celular e eluato que compreendem as ditas composições e usos terapêuticos das mesmas
HK40083648A (zh) 生物藥物組合物和相關方法
JP2022544850A (ja) 抗ｐｄ１抗体プロルゴリマブの水性医薬組成物およびその使用
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
WO2023185732A1 (zh) 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
HK40018067A (en) Anti-tigit antigen-binding proteins and methods of use thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted